FROM THE OTHER BOARD:

A MESSAGE TO THE LONGS THE SHORTS THE PUMPERS AND THE BASHERS

I usually do not post on these boards. I do however visit them from time to time to see if I can learn anything. I usually don't, but sometimes I find an investor here who knows something about his investment and I am always willing to learn.

I am here today becasue I am familiar with Lifeline and want to share what I know because it is important. I think some of you may have an inkling about the real potential of Lifeline but most of yor don't have a clue and are here only to make quick buck.

I made my first investment in Lifeline back in 2001 and have been increasing that investment ever since. I am a CPA and have been CFO of a major public company as well as smaller public companies. I am presently the CFO (part time)
of another Pink Sheet company and consultant to large and small companies, both public and private, none of which is Lifeline.

Lfeline is not only a company in the process of creating unique and innovative medical products and processes, it is also a great human interest story because its founders are dedicated to the creation of products that will save lives and serve humanity for years to come.

This company is on the cutting edge of how medicine will be conducted throughout the millennium. Dr. Bill Reeves, the founder knows more about medicine and medical research than all the medical doctors I have met in my lifetime. His research covers a broad spectrum of health care systems and his initial concentration in the early detection of the lethal female cancers of the breast and ovaries doesn't begin to scratch the surface of the total expanse of his research projects in process. He holds numerous patents on a wide variety of medical products and processess. The products you read about in the company's business plan are just the beginning of the extensive product line that will ultimately by what Lifeline becomes.

Jim Holmes, CEO is an experienced senior adsministrator and manager. Especially gifted at running a tight economic environment. Without Jim's astute and agile management style the company would not have survuved.

Lifeline is an anomaly as a Pink Sheet company. Here's why:
1. Pink Sheet companies do not receive exclusive U.S. distribution rights for the product lines of major medical product companies (Inion, Inc, and Anthronet, Gmbh)
2. Pink Sheet companies in the medical products industry do not receive endorsements from major internation medical educational and research orgainzations.
3. Pink Sheet companies do not engage successful senior executive consultants (Frank Clark and Carlo Micheletti) to kick off their marketing plans
4. Pink Sheet companies rarely engage major advertising agencies to kick off their marketing plans
5. Pink Sheet companies rarely have the senior executive management in place to take them to the next level
6 Pink Sheet companies rarely make historical product introductions at major international trade shows
Pink Sheet companies are rarely courted by major Wall Street Investment Bankers

If you consider the significance of the above you start to recognize the underlying strength of this company. They have announced their initial sales and although small, they are important. They have projected significant near term sales and have made the investment in the resources (sales organization, marketing materials and inventory in the warehouse)necessary to meet the projections.

They are ready to file their application with the SEC to become a full reporting company. The initial FORM 10 with audited financial statements must be cleared by the SEC before the company can trade its stock on the Bulletin Board or one of the U. S. Stock Exchanges. This process will take a minimum of three months but more likely will be six months before it is finished.

They should announce the closing of a major funding soon. When this will happen only the management knows. These kind of fundings take a long time and I know from experience that the closings of these transactions are painfully slow. Be patient, theirs will happen.

Like so many start ups Lifeline went to the Pink Sheets for cheap financing because they had no place else to go. It has been good to them over the last five years providing the funding for their research and keeping the company alive. Unfortunately this easy financing in not without its own set of problems as anyone who has followed the company is aware.

The price of their stock has been brutally attacked by illegal short selling and the total manipulation of a group of mnarket makers, most of whom have their offices in the same area of Jersey City, NJ. I have seen these attacks on other Pink Sheet and OTC/BB companies and rarely do any survive once the short sellers claim them as a victim.

Here again, Lifeline is an anomaly. The company has survived the continuing onslaught against its price per share until most recently when the market makers began a new technique of not processing major market price purchase orders. This tactic has brought the price down significantly in the last three weeks. The so called market makers who control and manipulate this stock it is rumored are the same ones who control the largest illegal short positions. People I know in the investment community have estimated the following short positions by broker, some of which are market makers in Lifeline:

Firm 1 750 million shares
Firm 2 450 million shares
Firm 3 300 million shares
Firm 4 200 million shares
Firm 5 150 million shares

The total shares outstanding are approximately 1 billion shares and the short position is almost twice that. This situation continues in spite of all the efforts of so many to get new rules in place only to be ignored by the manipulators. The agencies responsible to enforce the rules will only do so when enough pressure is brought to bear on them and this will come only when the investors get angry enough to do something about it both individuall and collectively. If you havn't signed the "online petition against naked short selling" go to their web site and do it now.

However, I do not believe we have to rely on the regulators to fix the short position with Lifeline. Short investors stay short only as long as they believe there is a valid economic reason to be short the stock. When the reason to be short goes away they cover and go long. The reason for the shorts in Lifeline is that they do not believe the company will make it. Once the shorts realize that the company is going to be successful they will abandon their short positions and they will then have to cover them. When that happens they will create a buying frenzy in this stock. Until that happens they will do everything in their power to destroy this stock. They will not win. The company has survived their worst and has too much going for it today to lose at this stage.

For the longs - stay the course. For the shorts enjoy your short victories, they won't last. For the pumpers and the bashers be gone.

quote:

---

Originally posted by realperson:
I plan to double my position as soon as QBID funds are freed up a bit.
Again my goal is for end of Year and this last post I found really makes me confident.
LBTT should have news early next week if they keep to their schedual, (JUS A SWAG)

---

quote:

---

Originally posted by Marva18:
Great Potential, any news out?

---

RENO, Nev., May 10, 2004 (BUSINESS WIRE) -- Jim Holmes, CEO of Lifeline Biotechnologies, Inc., (OTC:LBTT) responding to inquiries by shareholders, advised today that management of the Company knows of no valid business or economic reason for the recent decline in the per share price of the Company's common stock.

Holmes went on to say, "All markets suffer from volatility, and this is especially true on the Pink Sheets. Our stock has had a long steady climb over the past year with a number of peaks and valleys in between. As most of our investors are aware, Lifeline has been a long time target of short sellers, including large volumes of illegal naked short selling, which over the long haul has been a major contributor as a depressant on the price of our shares. However, also over this period, we have announced some of the most significant achievements in our history, and we believe these bear, to a great degree, in the growth of our share value.

"It was our expectation that our problems with the short sellers would be reduced, and eventually eliminated, when the SEC and NASD issued new rules and regulations to block illegal activities within short selling. It would appear, however, that as of yet these rules have not been effective, because the short abuses have not stopped. As a matter of fact, it appears in some respect they have only gotten worse. For the past three weeks market makers who appear to be most exposed by the short positions in Lifeline stock have extended their illegal activities to selectively excluding the processing of large purchase orders for our stock. We are currently reviewing with legal counsel the steps we can take to deal with these latest activities."

Holmes continued, "By way of review, I would like to reiterate some the major accomplishments that we have communicated to the financial community over the past six months. These include:

1. Our recent R&D accomplishments for our First Warning System(TM) which assists in the early detection of breast cancer. Specifically, Dr. Reeves' discovery that different breast lesions appear to have their own specific chaotic wave forms which have never been seen before. These findings will be the subject of a lecture Dr. Reeves has been asked to give at the upcoming International Conference on Cancer and Rhythm this fall.

"Dr. Louis Keith, the company's medical director, is also an invited speaker to the conference.

"Dr. Reeves has had several clinical papers accepted for publication concerning various critical phases of cancer development that raise several questions about present day detection of breast cancer. The company has prepared several patent applications to protect these new discoveries.

2. Our sales and marketing efforts are reality. We have had two major sales training seminars and now have sales representation in most major medical markets in the US. US product sales orders have been received and shipments have begun.

"As a result of our recent introduction of our MastaScope(TM) at the European Breast Cancer Conference in Hamburg, our International Director of Marketing and Sales, Carlo Micheleti, is attending a special meeting of the Egyptian National Cancer Institute this week to present Lifeline's MastaScope(TM) technology and products. In June he will attend a conference in Croatia and expects several orders. In July, Carlo will attend the InterAmerican Breast Conference in Cancun.

"Further, as a result of attending the Breast Surgeon's Conference in Las Vegas last month, US shipments of MastaScopes(TM) have begun.

"We expect to meet our sales goals and be running at an annual rate of $5 million by the end of this year. This rate of sales could be at a profitable level.

3. Funding - Regarding additional funding, the Company has one firm offer and several pending offers. Senior management will be in New York this week to explore several additional alternative sources.

4. The financial audit is underway and should conclude in June. Following the completion of the audit, management anticipates a filing with the SEC. Once the filing is cleared by the SEC, management expects to apply for a listing on the OTC-BB.

"Though all of the risks are not behind us, our Company is stronger right now than we have ever been. We believe what you are seeing in our share price is a last ditch and desperate attempt by the short sellers to convince our investors that they will win and the company will lose.

"Believe me, they are wrong. We are winning: The signs are all around us. We have struggled for a long time and the results of our efforts are coming to fruition. We will win and the shorts will lose."

Lifeline's website address: www.lbti.com

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe," "expects," "projects," "forecasts," "intends," "will," "anticipated," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and subject to the safe harbor created by the Act. All statements contained in the foregoing are forward-looking statements that may involve risks and uncertainties.

SOURCE: Lifeline Biotechnologies, Inc.

quote:

---

Originally posted by realperson:
I plan to double my position as soon as QBID funds are freed up a bit.
Again my goal is for end of Year and this last post I found really makes me confident.
LBTT should have news early next week if they keep to their schedual, (JUS A SWAG)

---

Yes I got one right
News out
They seem to follow a scheual
Dave

GLTA

quote:

---

Originally posted by realperson:
Yes I got one right
News out
They seem to follow a scheual
Dave

---

quote:

---

Originally posted by WWJD-thru-me:
I think this is great news. LBTT has been making progress and if they follow thru with getting on the OTC this summer we will see huge gains. I don't like to project prices but I think this company is way undervalued. I plan on buying more, I would like some around .0165 or so. That has been it's recent price. DD-IMO-GLTA-Debi

---

Once it hits bottom, it can only go up!

Todays numbers on LBTT May 19
Last Trade 0.014
Volume 4,632,809

May 27, 2004

RENO, Nev., May 27, 2004 (BUSINESS WIRE) --

Jim Holmes, CEO Lifeline Biotechnologies Inc. (OTC: LBTT), announced the company has entered into a contract to supply its proprietary Mastascope(TM) to its recently acquired Middle Eastern distributor, New Horizon Investment and Development. The Mastascope(TM) is designed for physicians to utilize in cases of women's nipple discharge and provides for the examination of the interior of the breast ducts to determine the source of the discharge. The device could save many needless surgeries. The ducts of the breast is where the vast majority of breast cancers originate.

Carlo Micheletti, Lifeline's director of international marketing and sales, just returned from Egypt where the distributorship agreement and an initial order were finalized. Micheletti noted, 'New Horizon Investment and Development, located in Cairo, Egypt, is a well-established medical device company. New Horizon has been in business over 12 years and employs 15 people. The company has several organizational alliances operating throughout the Middle Eastern region. In addition to Egypt, the contract granted to New Horizon includes the countries of Saudi Arabia, Kuwait, Yemen, Oman, Bahrain, Qatar, Jordan, Syria, Lebanon, Algeria, Libya, Tunisia, and Morocco. The distribution contract requires the minimum sales of $1,100,000 over the next four years. Other companies represented by New Horizon include Siemen's Ultrasound Systems, iCad Mammo Readers, Select Surgical for OB/GYN products, to name a few.'Micheletti went on to say, 'This distributorship is the result of the Mastascope(TM) being introduced last March at the European Breast Surgeon's conference in Hamburg, Germany. There are numerous other prospects that were obtained at the conference and we are following up on those as quickly as possible.'

Lifeline's Web site address: lbti.com

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words 'believe,''expects,''projects,''forecasts,''intends,''will,' 'anticipated,''could,'or 'may,'and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

SOURCE: Lifeline Biotechnologies Inc.

Lifeline Biotechnologies Inc. Jim Holmes, 775-324-1933 jholmes777@aol.com or jholmes@lbti.com or Stock Enterprises Investor Relations, 866-242-2405 (toll free) stockenter@aol.com

Customize your Business Wire news &multimedia to match your needs. Get breaking news from companies and organizations worldwide. Logon for FREE today at www.BusinessWire.com.

Copyright (C) 2004 Business Wire. All rights reserved.

I think when it was trading in the .025 area last time already had news that everyone was expecting "built in".

I am looking for this one to be 10X to 50X current PPS in the future. Again I think it is a long term hold.

This news today (in my opinion) was not so great that it is going to cause it to break the previous resistance. I also do not think it was even strong enough to make it hold very long if it sees the .025 level again (soon).

I hope the spike on this news continues tomorrow. It is my intention to flip some of this. (actually unlod the shares I picked up before the dip) and hold the shares I bought in the .012 area.

I think we will se the .012 area again before this thing moves for real.

Further, I think that this one will actually GROW into being worth more over time. (think GZFX) I don't see this one running and holding some high PPS.

The company is great (IMO). They have great ideas, great products and they are making money. I do not think they have to sell their stock to survive. Therefore I think they can out last the temporary games the MM's have in mind.

Let the price go where it may in the short term, I am long on this one.

Hope I can get rid of the shares I bought when it was trading in the higher range weeks ago and double up if it falls again. We will see.

Everything here is my opinion. I DO NOT make a living doing this and often do not even make money doing this.

Paul